← Browse by Condition
Medical Condition
advanced gastroesophageal junction adenocarcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3, Phase 2
ClinicalMetric tracks all active clinical trials for advanced gastroesophageal junction adenocarcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — advanced gastroesophageal junction adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for advanced gastroesophageal junction adenocarcinoma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for advanced gastroesophageal junction adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced gastroesophageal junction adenocarcinoma?
advanced gastroesophageal junction adenocarcinoma research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced gastroesophageal junction adenocarcinoma clinical trial?
Eligibility criteria for advanced gastroesophageal junction adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 2
Phase 3 1
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT06028737 Phase 2, Phase 3
Recruiting
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Enrollment
150 pts
Location
Lithuania, Ukraine
Sponsor
Ukrainian Society of Clinical ...
NCT05733000 Phase 2
Recruiting
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Enrollment
94 pts
Location
United States
Sponsor
Northwestern University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology